Kalaris Therapeutics Secures $50 Million Funding to Advance TH103 for Neovascular AMD Treatment
Key Insights
Kalaris Therapeutics (search) raised $50 million in an oversubscribed private placement from institutional investors including ADAR1 Capital Management (search) and RTW Investments (search).
The funding will support clinical development of TH103, a treatment for neovascular age-related macular degeneration (search), extending operations into Q3 2027.
The company was founded by Dr. Napoleone Ferrara, whose pioneering research led to the development of anti-VEGF therapy for retinal diseases (search).
Kalaris Therapeutics (search) has successfully completed a $50 million private placement to fund the clinical development of TH103, its investigational treatment for neovascular age-related macular degeneration (search) (AMD). The oversubscribed financing round attracted participation from both new and existing institutional investors, demonstrating strong confidence in the company's retinal disease pipeline.
Funding Details and Investor Participation
The private placement included securities sales to a select group of institutional accredited investors, with notable participation from ADAR1 Capital Management (search), Coastlands Capital, Invus, RTW Investments (search), Samsara BioCapital, and Woodline Partners LP. The transaction structure involved selling 4.2 million shares of common stock at $10.00 per share, along with pre-funded warrants to purchase 800,000 shares at $9.9999 per warrant.
The securities were priced at a premium to Kalaris' closing price on The Nasdaq Global Market over the prior five trading days, indicating investor confidence in the company's prospects. Morgan Stanley (search) and Leerink Partners (search) served as lead placement agents, with William Blair also acting as a placement agent for the transaction.
Strategic Use of Proceeds
Based on current operating plans, Kalaris expects the net proceeds from the private placement, combined with existing cash, cash equivalents, and short-term investments, will fund operations into the third quarter of 2027. The company intends to use these funds primarily to advance the clinical development of TH103 for neovascular AMD (search), along with working capital and general corporate purposes.
Company Background and Leadership
Kalaris Therapeutics (search) was founded by Dr. Napoleone Ferrara, whose pioneering research led to the development of anti-VEGF therapy. The clinical-stage biopharmaceutical company focuses on developing and commercializing treatments for prevalent retinal diseases (search), addressing sight-threatening conditions with significant unmet medical needs.
Market Position and Development Timeline
The company is positioned to advance novel therapeutic approaches for patients with retinal conditions, building on the foundational work in anti-VEGF therapy. The private placement is expected to close on or about December 19, 2025, subject to satisfaction of customary closing conditions.
The securities issued in the private placement have not been registered under the Securities Act of 1933, and pursuant to the securities purchase agreement, Kalaris has agreed to file a registration statement with the SEC to register the resale of the shares and warrants issued in the transaction.